Knocking down CEP55 levels delayed epithelial-mesenchymal transition (EMT) and increased cisplatin sensitivity in breast cancer (BC) by inhibiting the P38MAPK and ERK1/2 pathways [12]. Here, CEP55 is linked to breast cancer.